Samuel T. Milliken

1.8k total citations
44 papers, 1.0k citations indexed

About

Samuel T. Milliken is a scholar working on Oncology, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Samuel T. Milliken has authored 44 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 13 papers in Hematology and 9 papers in Pathology and Forensic Medicine. Recurrent topics in Samuel T. Milliken's work include Hematopoietic Stem Cell Transplantation (10 papers), Lymphoma Diagnosis and Treatment (8 papers) and Viral-associated cancers and disorders (6 papers). Samuel T. Milliken is often cited by papers focused on Hematopoietic Stem Cell Transplantation (10 papers), Lymphoma Diagnosis and Treatment (8 papers) and Viral-associated cancers and disorders (6 papers). Samuel T. Milliken collaborates with scholars based in Australia, United States and United Kingdom. Samuel T. Milliken's co-authors include John J. Moore, Jeff Szer, Andrew Field, Deborah Marriott, Monica A. Slavin, C. Orla Morrissey, Ashish Bajel, Sharon C.‐A. Chen, Claire M. Vajdic and Jennifer Turner and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Clinical Infectious Diseases.

In The Last Decade

Samuel T. Milliken

39 papers receiving 1.0k citations

Peers

Countries citing papers authored by Samuel T. Milliken

Since Specialization

Citations

This map shows the geographic impact of Samuel T. Milliken's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samuel T. Milliken with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samuel T. Milliken more than expected).

Fields of papers citing papers by Samuel T. Milliken

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samuel T. Milliken. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samuel T. Milliken. The network helps show where Samuel T. Milliken may publish in the future.

Co-authorship network of co-authors of Samuel T. Milliken

This figure shows the co-authorship network connecting the top 25 collaborators of Samuel T. Milliken. A scholar is included among the top collaborators of Samuel T. Milliken based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Samuel T. Milliken. Samuel T. Milliken is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Rates of Fertility Discussions and Counseling Before, During, and After Anticancer Treatments 2025 ·Journal of the National Comprehensive Cancer Network ·Verity Chadwick, (unknown), Catherine So–kum Tang, Antoinette Anazodo, Rachel Dear, (unknown), (unknown), Samuel T. Milliken, Georgia McCaughan, Nada Hamad	0
2	Occupational exposure to extremely low-frequency magnetic fields and follicular lymphoma risk: a family case–control study 2023 ·Occupational and Environmental Medicine ·Michael K. Odutola, Marina T. van Leeuwen, Fiona Bruinsma, Geza Benke, Michelle C. Turner, Judith Trotman, Jennifer Turner, John F. Seymour, H. Miles Prince, Samuel T. Milliken, Campbell Tiley, Mark Hertzberg, Fernando Roncolato, Stephen Opat, (unknown), Emma Verner, Craig Underhill, Elisabeth Cardis, Graham G. Giles, Claire M. Vajdic	0
3	Factors determining whether diffuse large B‐cell lymphoma samples are detected by flow cytometry 2023 ·International Journal of Laboratory Hematology ·David M. Peng, (unknown), Steven Q. Le, (unknown), Min Qiu, Peter Earls, Andrew Field, (unknown), Matthew Law, Samuel T. Milliken, William A. Sewell	2
4	Dietary intake of animal-based products and likelihood of follicular lymphoma and survival: A population-based family case-control study 2023 ·Frontiers in Nutrition ·Michael K. Odutola, Marina T. van Leeuwen, Julie K. Bassett, Fiona Bruinsma, Jennifer Turner, John F. Seymour, H. Miles Prince, Samuel T. Milliken, Mark Hertzberg, Fernando Roncolato, Stephen Opat, (unknown), Campbell Tiley, Judith Trotman, Emma Verner, Michael Harvey, Craig Underhill, Geza Benke, Graham G. Giles, Claire M. Vajdic	0
5	Associations between early-life growth pattern and body size and follicular lymphoma risk and survival: a family-based case-control study 2022 ·Cancer Epidemiology ·Michael K. Odutola, Marina T. van Leeuwen, Jennifer Turner, Fiona Bruinsma, John F. Seymour, H. Miles Prince, Samuel T. Milliken, Mark Hertzberg, Judith Trotman, Stephen Opat, (unknown), Fernando Roncolato, Emma Verner, Michael Harvey, Campbell Tiley, Craig Underhill, Geza Benke, Graham G. Giles, Claire M. Vajdic	2
6	Country Report: The Report of Transplant Activity and Outcome During the First 12 Months at the First National Hematopoietic Stem Cell Transplant Center in Sri Lanka 2019 ·PubMed ·(unknown), (unknown), (unknown), Suresh Senan, (unknown), (unknown), (unknown), Samuel T. Milliken, John J. Moore, (unknown)	1
7	Post-transplant lymphoproliferative disease in heart and lung transplantation: Defining risk and prognostic factors 2015 ·The Journal of Heart and Lung Transplantation ·G. Kumarasinghe, (unknown), Andrew Parker, Ian Nivison‐Smith, Samuel T. Milliken, Anthony J. Dodds, Joanne Joseph, Keith Fay, Daniel David, M.A. Malouf, (unknown), A. Havryk, A. Keogh, Christopher S. Hayward, Eugene Kotlyar, Andrew Jabbour, Allan R. Glanville, Peter S. Macdonald, John J. Moore	38
8	Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial 2013 ·The Lancet Infectious Diseases ·C. Orla Morrissey, Sharon C.‐A. Chen, Tania C. Sorrell, Samuel T. Milliken, Peter Bardy, Kenneth F. Bradstock, Jeff Szer, Catriona Halliday, Nicole Gilroy, John J. Moore, Anthony P. Schwarer, Stephen Guy, Ashish Bajel, Adrian R Tramontana, Timothy Spelman, Monica A. Slavin	170
9	Serum macrophage inhibitory cytokine 1 in rheumatoid arthritis: A potential marker of erosive joint destruction 2007 ·Arthritis & Rheumatism ·David A. Brown, John J. Moore, Heiko Johnen, Tom Smeets, Asne R. Bauskin, Támara Kuffner, Helen Weedon, Samuel T. Milliken, Paul P. Tak, Malcolm Smith, Samuel N. Breit	83
10	Occupational Exposure to Pesticides and Risk of Non-Hodgkin's Lymphoma 2005 ·American Journal of Epidemiology ·Lin Fritschi, (unknown), Ann M. Hughes, Anne Kricker, Jennifer Turner, Claire M. Vajdic, AE Grulich, Samuel T. Milliken, JM Kaldor, Bruce K. Armstrong	71
11	Risk of non-Hodgkin lymphoma associated with occupational exposure to solvents, metals, organic dusts and PCBs (Australia) 2005 ·Cancer Causes & Control ·Lin Fritschi, Geza Benke, Ann M. Hughes, Anne Kricker, Claire M. Vajdic, Andrew E. Grulich, Jennifer Turner, Samuel T. Milliken, John Kaldor, Bruce K. Armstrong	62
12	A phase II study of Rituximab in rheumatoid arthritis patients with recurrent disease following haematopoietic stem cell transplantation 2004 ·Bone Marrow Transplantation ·John J. Moore, Dávid Ma, R. Will, Paul Cannell, M. Händel, Samuel T. Milliken	29
13	A phase II study of liposomal doxorubicin in the treatment of HIV‐related Kaposi's sarcoma 1998 ·Australian and New Zealand Journal of Medicine ·(unknown), Samuel T. Milliken, Daniel A. Goldstein, Craig Lewis, (unknown), Gerard Dolan, (unknown), David A. Cooper	18
14	Five year leukaemia‐free survival of 72% and 77% for early stage acute and chronic myeloid leukaemia treated by HLA‐identical sibling bone marrow transplantation 1996 ·Australian and New Zealand Journal of Medicine ·K Atkinson, K Downs, Anthony J. Dodds, A Concannon, Samuel T. Milliken	5
15	Phase I/II trial of filgrastim (r-metHuG-CSF), CEOP chemotherapy and antiretroviral therapy in HIV-related non-Hodgkin's lymphoma 1996 ·Annals of Oncology ·(unknown), D. Goldstein, Samuel T. Milliken, Craig Lewis, Jennifer Hoy, Brian J. Thomson, David A. Cooper	7
16	Autologous blood stem cell transplantation for haematological malignancy: treatment‐related mortality of 2% 1995 ·Australian and New Zealand Journal of Medicine ·K Atkinson, Anthony J. Dodds, Samuel T. Milliken, A Concannon, Keith Fay, Martin Harris, (unknown), D. Scott Lind, (unknown), J Rutovitz, Dana Rosenfeld, Michael Harvey, K Downs, (unknown), Jae‐Hoon Song, Adèle C. Green, (unknown), (unknown)	7
17	Unrelated volunteer bone marrow transplantation: initial experience at St Vincent's Hospital, Sydney 1993 ·Australian and New Zealand Journal of Medicine ·K Atkinson, K Downs, Anthony J. Dodds, (unknown), A Concannon, (unknown), Samuel T. Milliken, D. H. Staniforth	6
18	Human recombinant GM-CSF in allogeneic bone-marrow transplantation for leukaemia: double-blind, placebo-controlled trial 1990 ·The Lancet ·R Powles, C. W. Smith, J. Treleaven, Samuel T. Milliken, Campbell Tiley, T J McElwain, S Milan, E. C. Gordon‐Smith	103
19	Bone marrow transplantation—The Marsden experience 1987 ·Hematological Oncology ·(unknown), A. Lakhani, R Powles, A Nandi, A. Zuiable, Martin Gore, Garry Forgeson, J Treleaven, Samuel T. Milliken, Jeremy Millar	1
20	Mechanical ventilation of infants with severe hyaline membrane disease in a regional newborn intensive care unit 1980 ·Journal of Paediatrics and Child Health ·Peter Barr, Samuel T. Milliken	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact